Therapeutics: RAD52 homolog (RAD52); breast cancer 1 early onset (BRCA1); BRCA2

In vitro studies identified 6-hydroxy-DL-dopa as an allosteric inhibitor of RAD52 that could help treat BRCA1- or BRCA2-deficient cancers and leukemias. In a high throughput screen of a library of dru...